Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being de... Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. Mehr anzeigen
- Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p <...
- THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) - - Conference call and webcast to be held Monday, December...
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that...
- Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disease (TED); on track to report topline data from THRIVE-2 in chronic patients in...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.37 | 13.0722559294 | 18.13 | 20.5 | 17.06 | 2169767 | 19.04760015 | CS |
| 4 | -1.4 | -6.39269406393 | 21.9 | 23.65 | 17.06 | 1800366 | 19.92443527 | CS |
| 12 | -3.785 | -15.5857525221 | 24.285 | 27.2 | 17.06 | 1227874 | 21.37657155 | CS |
| 26 | 7.78 | 61.1635220126 | 12.72 | 27.2 | 11.85 | 1345047 | 19.22375688 | CS |
| 52 | -2.45 | -10.6753812636 | 22.95 | 27.2 | 11.4 | 1153345 | 18.20691974 | CS |
| 156 | -1.02 | -4.73977695167 | 21.52 | 39 | 9.47 | 759137 | 19.83635334 | CS |
| 260 | -0.89 | -4.1608228144 | 21.39 | 39 | 9.47 | 602510 | 19.66508765 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
